EssilorLuxottica says Stellest 2.0 myopia lenses cut progression by 0.51D at six months in China trial

• EssilorLuxottica reported interim six-month results from an ongoing randomized, double-blind clinical trial of Stellest 2.0 myopia-control lenses in China.
• Findings were first presented at a scientific symposium held alongside the ESCRS meeting in London.
• The lenses showed stronger myopia-control performance versus standard single-vision lenses, suggesting a faster treatment response.
• High wear-time compliance was reported, with comfort and adaptation broadly comparable to conventional lenses.
• The study continues, with the pre-specified one-year analysis set as the primary efficacy endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EssilorLuxottica SA published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.